AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06168422 — intervention group
Intervention type: DEVICE
Intervention: DES
Description: drug eluting stent
Study NCT06168422 — intervention group
Intervention type: DEVICE
Intervention: DCB
Description: drug-coated balloon
Study NCT05550597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl
Description: Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia
Study NCT05550597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia Ultrasound-guided Transversus Abdominal plane block using Bupivacaine 0.25% Injectable Solution
Study NCT05892016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: grafted with bone particle and covered with a subepithelial connective tissue graft
Study NCT05892016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: grafted with bone particle and covered with vascularized interpositional periosteal connective tissue graft
Study NCT05892016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: grafted with bone particle and covered with a collagen membrane
Study NCT05892016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: grafted with bone particle and covered with a Cytoplast
Study NCT05231655 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional drug screen
Description: High-throughput ex-vivo drug screen of cells processed directly from solid tumours to determine sensitivity / resistance profiles
Study NCT04930003 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QazCoVac-P -COVID-19 Subunit Vaccine
Description: QazCoVac-P (Subunit) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
Study NCT04930003 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
Study NCT06250088 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Emdogain (EMD) - test
Description: Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the resulting fragments will be extracted with a minimally invasive approach. A multiple drilling axis tooth-supported surgical guide will be used to prepare the recipient site in accordance with the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt the computer assisted rapid prototyping (CARP) model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric if ostectomy is required, and avoiding the use of elevators or forceps over the root surface. Extraorally, (Emdogain) EMD will be applied to the root surface of the donor tooth. Sutures will be applied to closely adapt the soft tissues around the autotransplanted tooth. A semi-rigid orthodontic wire will be used to splint the tooth to the mesial and distal adjacent teeth
Study NCT06250088 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the resulting two fragments will be extracted with a minimally invasive approach. A multiple drilling axis tooth-supported surgical guide will be used to prepare the recipient site in accordance with the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt thecomputer assisted rapid prototyping (CARP) model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if ostectomy is required, and avoiding the use of elevators or forceps over the root surface. No Emdodain (EMD). Sutures will be applied to closely adapt the soft tissues around the autotransplanted tooth. A semi-rigid orthodontic wire will be used to splint the tooth to the mesial and distal adjacent teeth
Study NCT06250088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham group
Description: Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the resulting two fragments will be extracted with a minimally invasive approach. A multiple drilling axis tooth-supported surgical guide will be used to prepare the recipient site in accordance with the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt thecomputer assisted rapid prototyping (CARP) model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if ostectomy is required, and avoiding the use of elevators or forceps over the root surface. No Emdodain (EMD). Sutures will be applied to closely adapt the soft tissues around the autotransplanted tooth. A semi-rigid orthodontic wire will be used to splint the tooth to the mesial and distal adjacent teeth
Study NCT05885269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A applied topical Clobetasol Propionate
Description: Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months
Study NCT05885269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B applied topical Tacrolimus
Description: Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.
Study NCT06385613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-based stoma care education group
Description: Individuals included in the intervention group will be given mobile-based stoma care trainings before surgery, on the 3rd postoperative day, on the day of discharge, and on the 1st and 3rd months after discharge, and their effectiveness will be measured using data collection forms.
Study NCT06483386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine
Description: Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine
Study NCT04833426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Topical gel containing testosterone
Study NCT04833426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical gel without active substance
Study NCT00290381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxagen OC000459
Study NCT05039320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bactoblis
Description: dissolve the tablets in the mouth once a day for 4 weeks
Study NCT05039320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dissolve the tablets in the mouth once a day for 4 weeks
Study NCT05180370 — intervention group
Intervention type: OTHER
Intervention: Questionnaies
Description: Data entry staff who will be assigned to the centers for 2 weeks will apply a questionnaire consisting of different questions to the patients referred to them by clinicians with the diagnosis of HF (presented in the appendix to this protocol). In addition, Pittsburg Sleep Quality Index will be applied to all cases.
Study NCT04830761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation
Description: The key constructs targeted by the motivational module are attitudes towards the target behavior, risk perception, outcome expectancies and self-efficacy. The intervention includes the following techniques: information about health consequences, salience of consequences, goal setting (behavior), problem solving, verbal persuasion about capabilities, focus on past success (Michie et al., 2013)
Study NCT04830761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit
Description: The goal of the habit module is to guide participants to perform correct hand hygiene at self-selected key times repeatedly. The aim is that the behavior will be translated into a habit. The intervention includes the following techniques: Information about antecedents, self-monitoring of behavior, action planning, prompts/cues, habit formation, behavioral practice/ rehearsal, prompts/cues (physical cue) (Michie et al., 2013).
Study NCT04830761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social
Description: The key constructs targeted by the social module are perceived norms including descriptive norms and injunctive norm. The intervention includes the following techniques: Monitoring of behavior by others, social incentive, social comparison, social reward, restructuring the physical environment, information about others approval, credible source, information about health consequences, feedback on behavior (Michie et al., 2013).
Study NCT05707715 — intervention group
Intervention type: DEVICE
Intervention: XSensor
Description: A pressure mapping system (X3 SENSOR PX 100:64.160.02, X-Sensor®, Calgary, Canada) was used to record the pressure distribution in mmHg of the head and shoulder section \[18,19\]. Pressure distribution was recorded for 1 minute for each lying position. The purpose of these measurements was to describe the pressure distribution created by the participants in the pillow and the supported areas, as well as to find out the differences that may occur between the pillows. Lower pressure values measured by the device were defined as high comfort, while more contact of the head area with the pillow was accepted as high support.
Study NCT04838964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003
Description: Administrated intravenously
Study NCT04912700 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Full or partial reception of vaccine
Study NCT05849571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coconut oil
Description: • The patient's mouth is evaluated using the World Health Organization Mucositis Classification and the International Child Mucositis Evaluation Scale (ChIMES) on days 0, 7, and 14, and after each assessment, the frequency of oral care is determined and applied for 21 days. The final assessment is made on Day 21.
Study NCT04747821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adsorbed COVID-19 (Inactivated) Vaccine
Description: Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
Study NCT04662294 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR T-cells
Description: Each subject receive CD70 CAR T-cells by intravenous infusion
Study NCT05426109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut snacks
Description: Participants will undergo a 10-week diet and weight training regimen to promote healthy weight gain. These participants will receive seven 500 kcal peanut-containing (whole peanuts or peanut butter) snacks each week and consume one snack per day throughout the study. They will also perform a series of weight training exercises supervised by a personal trainer on 3 days per week.
Study NCT05426109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No peanut-containing snacks
Description: Participants will undergo a 10-week diet and weight training regimen to promote healthy weight gain. These participants will receive seven 500 kcal non-peanut-containing high carbohydrate snacks each week and consume one snack per day throughout the study. They will also perform a series of weight training exercises supervised by a personal trainer on 3 days per week.
Study NCT06333405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Procedure: Fecal Microbiota Transplantation~Fecal Microbiota as a suspension obtained from healthy unrelated donor (woman in 3rd trimester of pregnancy) introduced two times per treatment:~* as a deep rectal infusion, via Foley's catheter inserted under ultrasound control, twice 6 hours apart, between 3 and 6 days after birth and/or up to 14 days~* Other Names: MBiotix HBI
Study NCT05710094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoftOx Biofilm Eradicator (Groups 1 to 7)
Description: SBE is a water-based formulation containing hypochlorous acid (HOCl) at concentrations of 500-1000 µg/mL and acetic acid (HAc) at concentrations of 1-3 %. Both active ingredients are naturally occurring molecules and have a long history of safe use in medicinal products and in solutions approved as medical devices. Both molecules, exhibit broad-spectrum antimicrobial activity at the concentrations present in SBE. The antimicrobial effect of HOCl is rapid and powerful by acting on and disrupting the function of key microbial molecules such as proteins, lipids, and nucleic acids, while remaining safe to mammalian cells and not promoting the emergence of new resistant microbes. Moreover, HOCl is active against biofilms, and some studies suggest that HOCl may also increase oxygenation of the wound site leading to improved healing.
Study NCT05710094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterile isotonic saline (Groups 1 to 4)
Description: Sterile isotonic saline was used as placebo because it is part of standard of care, used as an irrigation solution at dressing change and has the same appearance as SBE
Study NCT04812795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally tailored anti-smoking messages
Description: Anti-smoking messages that are culturally tailored for sexual minority women.
Study NCT04812795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-culturally tailored interventions
Description: Anti-smoking messages that are not culturally tailored for sexual minority women.
Study NCT04742309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pecs-2 block (single injection)
Description: For Pecs-2 blocks, the needle will be advanced to the tissue plane between the pectoralis major and minor muscles at the vicinity of the pectoral branch of the acromiothoracic artery where 10 mL of local anesthetic will be deposited. In a similar manner, 20 mL will be deposited at the level of the third rib above the serratus anterior muscle with the intent of spreading injectate to the axilla. The study fluid will be ropivacaine 0.3% with epinephrine.
Study NCT04742309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block (single injection)
Description: For paravertebral blocks, ropivacaine 0.5% (with epinephrine) 9 mL will be administered at each of two levels per side: the T3 and T5 levels for sides without axillary involvement; and at the T2 and T4 level for sides with axillary involvement.
Study NCT04633902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg BID daily
Study NCT04633902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV eveyr 3 weeks (for up to 2 years)
Study NCT06114498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Transthoracic echocardiography at rest: with determination of epicardial fat tissue thickness, intensity of mitral regurgitation.
Study NCT06114498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bioimpedance
Description: Bioelectrical impedance analysis research
Study NCT06114498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunoassay
Description: Enzyme immunoassay of heat shock proteins in blood serum
Study NCT06114498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Routine biochemistry
Description: Measuring of routine biochemical parameters (glucose, total protein, creatinine, urea, uric acid, total bilirubin, direct bilirubin, total cholesterol, triglycerides, low and high density lipoprotein cholesterol, Lactate dehydrogenase, creatine phosphokinase, aspartate aminotransferase, alanine aminotransferase, sodium, potassium and special (C-reactive protein, N-terminal pro b-type natriuretic peptide)
Study NCT06370338 — intervention group
Intervention type: OTHER
Intervention: Delphi Questionnaire
Description: Experts will be approached to participate in the research via email. If the experts agree to participate they will check 'yes' in the email with the informed consent and will be directed to the Qualtrics survey. If the expert decides to decline consent they will check 'no' in the email and will not be enrolled. Subjects who agree to participate will undergo 2 phases of questions with three rounds of the same questions in each phase. This Delphi survey research involves Phase 1 and Phase 2 of questioning, each phase involves up to 3 rounds of questions to determine agreement or disagreement. Each round will take approximately 20 minutes to complete, and your responses will remain completely confidential. For both phases, the questions will either be 7-point Likert or multiple choices. For both phases, the group of questions will be sent up to three times until we obtain agreement (up to 80% of agreement consensus). Questions that have obtained agreement will be removed in each round.
Study NCT05287334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography measurement
Description: During standard blood donation, donors' chest bioimpedance will be measured using electrical impedance tomography.
Study NCT06152744 — intervention group
Intervention type: OTHER
Intervention: Monitoring membrane lung function at different altitudes
Description: The altitude in Beijing is 100m, while the altitude in Xining, Qinghai is 2600m. We will monitor the partial pressure of post-ML arterial oxygen in ECMO patients in these two locations and evaluate whether the normal values of membrane lung function are consistent in different altitudes.
Study NCT05983575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIPUS-Brain
Description: Transcranial low-power pulsed-wave ultrasound device
Study NCT05983575 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05598710 — intervention group
Intervention type: PROCEDURE
Intervention: Pigtail Insertion
Description: Pigtail is inserted for any reason of ureteral obstruction except for malignant
Study NCT06464926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterra Therapy System
Description: The Enterra Therapy System is a gastric electrical stimulator system consisting of an implantable pulse generator (Enterra II Model 37800 neurostimulator); two implantable unipolar leads (Enterra Model 4351-35 intramuscular); and device programmer (N'Vision Clinician Programmer Model 8840 with Model 8870 Application Card).~The programmable neurostimulator operates on a sealed battery and electronic circuitry to provide controlled electrical pulse stimulation through the implanted lead system. A clinician programmer is used to program the neurostimulator and adjust stimulation settings to programmable parameters and stimulation options.
Study NCT06665971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Description: Dosage form: Subcutaneous injection Dosage: 300 mg/ 2ml Dosage frequency: Once a week Duration: 12 weeks
Study NCT04847102 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SARS-CoV-2 mRNA Vaccine
Description: The SARS-CoV-2 mRNA Vaccine is formulated by encapsulating the mRNA, which encodes the receptor-binding domain (RBD) of spike glycoprotein (S protein) of SARS-CoV-2 and is transcribed in-vitro by the corresponding DNA template, in lipid nanoparticles (LNPs). This vaccine is presented as a white to off-white dispersion for injection.~Active substances: mRNA encoding the RBD of the S protein of SARS-CoV-2.~The vaccine is supplied in single-dose pre-filled syringe with 0.5 mL dispersion for intramuscular injection. Each dose (0.5 mL) of the vaccine contains:~15 μg of mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2, 0.339 mg of total lipids (including lipid 9001, cholesterol, DSPC, DMG-PEG2000).
Study NCT04847102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA Vaccine
Description: The SARS-CoV-2 mRNA Vaccine is formulated by encapsulating the mRNA, which encodes the receptor-binding domain (RBD) of spike glycoprotein (S protein) of SARS-CoV-2 and is transcribed in-vitro by the corresponding DNA template, in lipid nanoparticles (LNPs). This vaccine is presented as a white to off-white dispersion for injection.~Active substances: mRNA encoding the RBD of the S protein of SARS-CoV-2.~The vaccine is supplied in single-dose pre-filled syringe with 0.5 mL dispersion for intramuscular injection. Each dose (0.5 mL) of the vaccine contains:~15 μg of mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2, 0.339 mg of total lipids (including lipid 9001, cholesterol, DSPC, DMG-PEG2000).
Study NCT04847102 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride solution, 0.5 mL/vial
Study NCT04847102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride solution, 0.5 mL/vial
Study NCT05947227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buteyko breathing technique
Description: Group A : will be treated with manual chest physiotherapy \& Buteyko Breathing exercise
Study NCT05947227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing technique.
Description: Group B : will be treated with manual chest physiotherapy \& Diaphragmatic Breathing Treatment evaluation will be done after 8 weeks through 6MWT \& St George respiratory Questionnaire. Patients will perform technique 5 times a weeks for 8 weeks
Study NCT06710899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine Hippurate 1g BD
Description: Methenamine Hippurate 1g BD for 6 months
Study NCT06710899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine Hippurate 1g BD + Vitamin C 1g BD
Description: Methenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months